Tags

Type your tag names separated by a space and hit enter

Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.
Eye (Lond) 2005; 19(2):163-70E

Abstract

PURPOSE

To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration.

METHODS

The prospective comparative nonrandomized clinical interventional study included 187 consecutive patients with progressive exudative age-related macular degeneration, divided into a study group of 115 patients receiving an intravitreal injection of 25 mg triamcinolone acetonide, and a control group of 72 patients without treatment. The mean follow-up was 6.0+/-4.2 months.

RESULTS

Visual acuity increased significantly (P=0.03) in the study group, and decreased significantly (P=0.01) in the control group, at 1 month and 3 months after start of the study. Between the study group and control group, the differences in change of visual acuity were significant (P=0.001). In the study group, the number of patients with an increase in visual acuity of 2 or more Snellen lines was significantly (P=0.001) larger than in the control group. Correspondingly, the number of patients with a decrease of 2 or more Snellen lines was significantly (P=0.007) smaller in the study group. In all, 43 (37.4%) patients of the study group experienced an increase in best visual acuity by 2 or more Snellen lines.

CONCLUSIONS

Visual acuity increased in patients with exudative age-related macular degeneration at 1 month and 3 months after an intravitreal injection of 25 mg triamcinolone acetonide.

Authors+Show Affiliations

Department of Ophthalmology, Faculty of Clinical Medicine, Mannheim of the University, Heidelberg, Germany. Jost.Jonas@ma.augen.uni-heidelberg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

15218517

Citation

Jonas, J B., et al. "Exudative Age-related Macular Degeneration Treated By Intravitreal Triamcinolone Acetonide. a Prospective Comparative Nonrandomized Study." Eye (London, England), vol. 19, no. 2, 2005, pp. 163-70.
Jonas JB, Degenring RF, Kreissig I, et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye (Lond). 2005;19(2):163-70.
Jonas, J. B., Degenring, R. F., Kreissig, I., Friedemann, T., & Akkoyun, I. (2005). Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye (London, England), 19(2), pp. 163-70.
Jonas JB, et al. Exudative Age-related Macular Degeneration Treated By Intravitreal Triamcinolone Acetonide. a Prospective Comparative Nonrandomized Study. Eye (Lond). 2005;19(2):163-70. PubMed PMID: 15218517.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. AU - Jonas,J B, AU - Degenring,R F, AU - Kreissig,I, AU - Friedemann,T, AU - Akkoyun,I, PY - 2004/6/26/pubmed PY - 2005/6/4/medline PY - 2004/6/26/entrez SP - 163 EP - 70 JF - Eye (London, England) JO - Eye (Lond) VL - 19 IS - 2 N2 - PURPOSE: To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. METHODS: The prospective comparative nonrandomized clinical interventional study included 187 consecutive patients with progressive exudative age-related macular degeneration, divided into a study group of 115 patients receiving an intravitreal injection of 25 mg triamcinolone acetonide, and a control group of 72 patients without treatment. The mean follow-up was 6.0+/-4.2 months. RESULTS: Visual acuity increased significantly (P=0.03) in the study group, and decreased significantly (P=0.01) in the control group, at 1 month and 3 months after start of the study. Between the study group and control group, the differences in change of visual acuity were significant (P=0.001). In the study group, the number of patients with an increase in visual acuity of 2 or more Snellen lines was significantly (P=0.001) larger than in the control group. Correspondingly, the number of patients with a decrease of 2 or more Snellen lines was significantly (P=0.007) smaller in the study group. In all, 43 (37.4%) patients of the study group experienced an increase in best visual acuity by 2 or more Snellen lines. CONCLUSIONS: Visual acuity increased in patients with exudative age-related macular degeneration at 1 month and 3 months after an intravitreal injection of 25 mg triamcinolone acetonide. SN - 0950-222X UR - https://www.unboundmedicine.com/medline/citation/15218517/Exudative_age_related_macular_degeneration_treated_by_intravitreal_triamcinolone_acetonide__A_prospective_comparative_nonrandomized_study_ L2 - http://dx.doi.org/10.1038/sj.eye.6701438 DB - PRIME DP - Unbound Medicine ER -